Skadden, Arps, Slate, Meagher & Flom·FDA / LIFE SCIENCES REGULATORY
Key takeaways from Skadden panel on FDA, patent & antitrust scrutiny
A September 2026 panel by Skadden highlighted growing regulatory scrutiny of life‑science firms and the strategic importance of patent and antitrust considerations.
fda-regulationlife-sciencespatent-strategyantitrust-riskskadden-panel
Read the original firm alert → Thursday, October 29, 2026